Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aap2-M1
- Development stage
- Discontinued
- Lead developer
- ContraFect
- Modality
- Peptides
01
Overview
**Aap2-M1** is an investigational synthetic antimicrobial peptide from ContraFect developed within the company's amurin peptide program for drug-resistant **Gram-negative bacterial infections**. Publicly available information indicates it remained at the **preclinical** stage and was later **discontinued**. The peptide has been described as a **cell wall inhibitor** with antibiofilm activity, including reported ex vivo eradication of *Stenotrophomonas maltophilia* biofilm in infected hemodialysis catheter material, but specific molecular target details, formulation, and clinical pharmacology have not been clearly disclosed in accessible primary sources.
- Other names
- amurin peptide candidate Aap2-M1
Beyond the preview
Go deeper on Aap2-M1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aap2-M1.